Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03238469
Other study ID # WAVE trial
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date April 1, 2018

Study information

Verified date June 2018
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With microwave ablation (MWA), using the heat generated from electromagnetic waves in the microwave energy spectrum, hair follicles and apocrine glands in the (hypo)dermis are ablated through thermolysis. MWA was recently approved for the treatment of axillary hyperhidrosis (miraDry) and removal of axillary hair (miraSmooth). By permanent removal of hairs and sweat glands, the investigators hypothesize a beneficial and long-term sustainable preventive effect of MWA in HS patients.


Description:

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease of the hair follicle, and is predominantly located in the axillary, inguinal and anogenital regions. Current treatment options for HS include systemic oral antibiotics, anti-TNFα, and surgery, which are used to treat the consequences rather than treating the primary pathogenesis of HS. With microwave ablation (MWA), using the heat generated from electromagnetic waves in the microwave energy spectrum, hair follicles, eccrine and apocrine glands in the (hypo)dermis are ablated through thermolysis. MWA was recently approved for the treatment of axillary hyperhidrosis (miraDry) and removal of axillary hair (miraSmooth). By permanent removal of hairs and sweat glands, the investigators hypothesize a beneficial and long-term sustainable preventive effect of MWA in HS patients.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date April 1, 2018
Est. primary completion date April 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Adult (= 18 years of age) male or female patients with mild HS and able to participate, willing to give written informed consent and to comply with the study restrictions;

- Minimum of 3 AN-count located in each axilla;

- Maximum of 5 AN-count located in each axilla.

Exclusion Criteria:

- Patients with >1 abscesses or draining fistulas per axillary region;

- AN-count = 5 in other regions than the axillary area;

- Any current and / or recurrent clinically significant skin condition in the treatment area other than HS;

- Surgical scars covering more than 25% of each individual axillary area;

- Open surgical wound(s) in the axillary areas prior to randomization;

- Use of anti-inflammatory or immunomodulatory medication (intralesional corticosteroids, oral antibiotics, biologics, prednisone) within 2 weeks prior to randomization;

- Contraindication for miraDry therapy;

- Heart pacemakers and other electronic device implants;

- Supplemental oxygen;

- Resistance to or history of intolerance of local anesthesia including lidocaine and epinephrine;

- Previous use of miraDry therapy or MWA in the axillary area;

- Previous use of successful laser or light therapy for hair removal in the axillary area;

- Use of botulinum toxin injections 6 months prior to randomization;

- Use of aluminiumhydroxychloride 1 month prior to randomization;

- Pregnant or lactating women at randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Microwave ablation
A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.

Locations

Country Name City State
Netherlands Erasmus University Medical Center Rotterdam

Sponsors (2)

Lead Sponsor Collaborator
M.B.A. van Doorn Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hidradenitis Suppurativa Clinical Response (HiSCR50) The proposed definition of 50% responders to treatment (HiSCR50 achievers) is: (i) at least a 50% reduction in ANs, (ii) no increase in the number of abscesses, and (iii) no increase in the number of draining fistulas from baseline 6 months
Secondary Hidradenitis Suppurativa Clinical Response (HiSCR30) The proposed definition of 30% responders to treatment (HiSCR30 achievers) is: (i) at least a 30% reduction in ANs, (ii) no increase in the number of abscesses, and (iii) no increase in the number of draining fistulas from baseline 6 months
Secondary Patient-reported number of HS flares The number of HS flares in the treated and untreated axillae. At baseline retrospective assessment on last month, and during follow-up prospective assessment using a diary where patients will report the number of acute boils per axilla. 6 months
Secondary Average number of hair containing follicles Dermatoscopy of three fields per axilla 6 months
Secondary Extent of sweat production Starch-Iodine test per axillary region 6 months
Secondary Patient-reported pain and pruritus Numerical rating scale (NRS) to assess pain and itch per axillary region 6 months
Secondary Incidence of (treatment-emergent) adverse events Safety and tolerability of the treatment 6 months
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2
Completed NCT01516749 - Anakinra as a Treatment for Hydradenitis Suppurativa Phase 2